New Oral Drug Delivers Brain-Calming Hormone by Bypassing Liver Metabolism

Researchers have solved a critical drug delivery challenge by developing an oral form of allopregnanolone, a naturally occurring brain hormone with powerful anti-anxiety and antidepressant properties. This breakthrough could transform treatment options for mood and anxiety disorders, conditions affecting millions worldwide and closely linked to accelerated aging and reduced healthspan.

The study involved creating a novel prodrug platform called Glyph, which attaches allopregnanolone to dietary lipid molecules using specialized linker chemistry. This design tricks the body into absorbing the drug through the lymphatic system rather than directly into the liver, where it would normally be rapidly destroyed.

Researchers tested multiple prodrug versions in laboratory and animal studies before advancing the most promising candidate, GlyphAllo, to human trials. The phase 1/2a clinical trial included 189 healthy participants who received single and multiple doses of the oral medication. A subsequent randomized, placebo-controlled trial used the validated Trier Social Stress Test to measure anxiety responses.

Results showed that GlyphAllo successfully delivered therapeutic levels of allopregnanolone to the bloodstream and significantly reduced cortisol stress responses compared to placebo. The drug was generally well-tolerated and demonstrated clear biological activity through GABA receptor modulation, the same pathway targeted by anti-anxiety medications.

This innovation addresses a major limitation in neuropsychiatric medicine, where many promising compounds fail due to poor oral bioavailability. Chronic stress and anxiety disorders accelerate cellular aging and increase disease risk, making effective treatments crucial for longevity. However, these are early-stage trials in healthy individuals, and effectiveness in actual patients with mood disorders requires further investigation.